Bayer receives NICE liver cancer approval for Nexavar

Pharmaceutical Company Product News

Bayer has announced that its liver cancer therapy Nexavar has been approved by the UK's National Institute for Health and Clinical Excellence (NICE).

The regulator has given a final appraisal recommending the sorafenib-based therapy for the treatment of advanced hepatocellular carcinoma in patients with a Child-Pugh grade A liver impairment, and who have failed or are unsuitable for surgical or loco-regional therapies.

“Bayer's Nexavar has been recommended as a liver cancer therapy by the National Institute for Health and Clinical Excellence.“

This comes after the drug was recently approved in this indication by the European Commission, and means Nexavar will be made routinely available on the NHS in England and Wales.

Nexavar was rejected by NICE last year over cost-effectiveness concerns, but the regulator has now acknowledged that the drug is the only licensed systemic treatment shown to improve overall survival for this disease, which is one of the most chemoresistant tumour types.

Amanda Cunnington, head of patient access at Bayer, said: "The new guidance from NICE now puts this funding on a more secure footing so patients and physicians in England will have routine access to a much-needed standard of care."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Pharmaceutical
Return to news